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Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral
EGFR tyrosine kinase inhibitor, shows supra-additive growth inhibition with irinotecan and fluoropyrimidines in xenograft models. We
designed a study to determine the tolerability and efficacy of gefitinib in combination with irinotecan, infusional 5-fluorouracil (5-FU)
and leucovorin (LV), on a 2-week schedule. Among 13 patients with advanced colorectal cancer, 10 required dose reductions of
irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with
neutropenic fever. One patient achieved partial response and seven had disease stabilisation. The combination of this standard
chemotherapy regimen with gefitinib is associated with excessive toxicity, suggesting an interaction at a pharmacokinetic or
pharmacodynamic level.
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The addition of irinotecan to 5-fluorouracil (5-FU) results in
response rates (RR) of 30–40%, and improved survival to about
14–16 months in metastatic colorectal cancer (Douillard et al,
2000; Saltz et al, 2000). Weekly and every 3-week schedules of
irinotecan demonstrate comparable toxicity and efficacy (Rougier
et al, 1997; Fusch et al, 2003), but the weekly combination of
irinotecan/5-FU shows excessive toxicity (Rothenberg et al, 2001).
The FOLFIRI regimen (Douillard et al, 2000) is less toxic, and
infusional 5-FU or capecitabine combinations are favoured (Han
et al, 2003; Tewes et al, 2003; Bajetta et al, 2004; Jordan et al, 2004).
Expression of the epidermal growth factor receptor (EGFR) has
been associated with outcome in colon cancer (Mayer et al, 1993;
Saloman et al, 1995). Gefitinib is an oral EGFR tyrosine kinase
inhibitor with an excellent safety profile. The combination of
gefitinib and irinotecan has shown supra-additive growth inhibi-
tion in colorectal cancer cell lines and in xenograft models
(Koizumi et al, 2004). In a human head and neck cancer cell line
treated with gefitinib before or during 50-deoxy-5-fluorouridine
(50-dFUR) treatment, there was a strong synergistic cytotoxic
activity, associated with altered target enzyme expression (Magne
et al, 2003). Clinical studies by Saltz and by Cunningham
demonstrated the therapeutic role of an antibody directed to
EGFR (Cunningham et al, 2004; Saltz et al, 2004).
We conducted a phase II study to determine the tolerability and
response with gefitinib together with irinotecan, infusional 5-FU,
and LV. The coadministration of these agents was associated with
unexpectedly severe gastrointestinal toxicity and myelosuppres-
sion, and the RR in this small cohort was modest at best.
PATIENTS AND METHODS
Eligibility
Eligible patients were over 18 years with advanced or recurrent
colorectal adenocarcinoma. No prior chemotherapy other than
adjuvant 5-FU was allowed. Patients were required to have
measurable disease. Eligibility criteria also included performance
status 0–2 (ECOG); adequate bone marrow (neutrophils
X1500mm
 3, platelets X100000mm
 3), renal (creatinine p1.5
times the upper limit of normal (ULN)), and hepatic (bilirubin
o1.5 times ULN, and AST/ALT p2 times ULN (o5  ULN if liver
metastasis) function. The study was approved by the University of
Pennsylvania institutional review board. All patients signed written
informed consent.
Pretreatment evaluation and follow-up
Pretreatment evaluation consisted of a history and physical
examination, full blood count, electrolytes, creatinine, liver
function tests and carcinoembryonic antigen (CEA), urinalysis,
electrocardiogram, and baseline imaging. Clinical, haematologic,
and biochemical evaluations were performed every 2 weeks.
Toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC).
Study design and treatment administration
This study was a nonrandomised safety and efficacy trial of 5-FU,
LV, and irinotecan in combination with gefitinib in patients with
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sadvanced colorectal cancer. Patients received LV 400mgm
 2 as a
2h intravenous (i.v.) infusion, followed immediately by bolus 5-FU
400mgm
 2 and a 22h i.v. infusion of 5-FU 600mgm
 2, on days 1
and 2, and irinotecan 180mgm
 2 as a 90min i.v. infusion during
LV on day 1 only (5-FU400–600/I180). Treatment was repeated
every 2 weeks and one cycle consisted of 28 days. Gefitinib 250mg
orally was administered continuously, beginning on day 1 (G250).
Antiemetic prophylaxis with a 5-hydroxytryptamine-3-receptor
antagonist and dexamethasone was used. Dose modifications were
made for myelosuppression (5-FU and irinotecan), diarrhoea (5-
FU, irinotecan, and gefitinib), mucositis (5-FU only), and skin rash
(gefitinib only). The LV dose was not modified.
Response evaluation
Measurable lesions were reassessed according to the Response
Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al,
2000) after cycles 2 and 4, and then every three cycles until
progression.
Statistical analysis
The purpose of this study was to assess the safety and efficacy of
gefitinib, irinotecan, LV, and 5-FU in combination. We wished to
be able to discern a toxicity rate of 29% with the new regimen.
With an accrual of 50 patients, we would have 80% power to
distinguish that level of toxicity from a 12% rate observed in prior
studies (Douillard et al, 2000). We targeted an RR of 60%, and
planned to accrue 50 patients to give a 95% confidence interval of
46–72%. All analyses were conducted using Stata 8.0, with two-
sided tests of hypotheses and a Po0.05 criterion for statistical
significance.
RESULTS
Patient characteristics
The demographic characteristics of the 13 patients are shown
(Table 1). All were evaluable for toxicity and 12 for response. One
patient was removed from study because of excessive first cycle
toxicity.
Treatment administration
A total of 10 patients required dose reductions of irinotecan and
5-FU (Table 2). The first seven patients received I180/5-FU400–
600/G250. Four experienced grade 3 neutropenia and/or dehydra-
tion during the first cycle of therapy and required 20% dose
reduction of irinotecan and 5-FU (I150/5-FU320–600/G250). Of
these seven, four required an additional 20% dose reduction (I120/
5-FU200–500/G250) because of dehydration or neutropenia.
Because of this unacceptable level of toxicity, subsequent patients
were treated at a reduced dose of irinotecan and 5-FU (I150/5-
FU320–600/G250). Of four patients treated at these doses, three
developed grade 4 neutropenia after the first cycle and two grade 3
diarrhoea, requiring an additional 20% dose reduction (I120/5-
FU200–500). For safety reasons, these doses were used in the
subsequent patients. This dose level was well tolerated by eight
patients in total (two new, six reduced) (Table 2). No dose changes
were made for gefitinib.
Toxicity
The most frequent grade 3/4 adverse events during this study were
gastrointestinal (mostly diarrhoea, 54%) and haematologic (neu-
tropenia, 62%) (Table 3). Seven patients (54%) developed grade 3
or 4 dehydration from diarrhoea, and all required hospitalisation.
Two were removed from study because of toxicity.
Eight patients (62%) developed grade 3 or 4 neutropenia, of
whom three experienced neutropenic fever. One expired from
sepsis after receiving one cycle of therapy. Of these eight patients,
four had concomitant grade 3/4 diarrhoea.
Acneiform skin rash occurred in eight patients, and was mild
and reversible. Grade 1/2 nausea and vomiting occurred in seven
patients (54%). Mucositis and fatigue were generally mild.
Response
The primary efficacy end point was RR. One patient achieved
partial response (PR) for seven cycles (8%, 95% CI 0–38%). Seven
of the 12 (58%, 95% CI 28–85%) evaluable patients had disease
stabilisation that persisted for more than six cycles in six. Based on
the excessive toxicity and low level of activity, after review of all
results, the trial was closed.
DISCUSSION
The combination of gefitinib with irinotecan, 5-FU, and LV
demonstrated excessive gastrointestinal and haematologic toxicity
in over half of the patients, despite the use of an infusional 5-FU
schedule. The tolerable doses of irinotecan and 5-FU with gefitinib
were one-third less than those commonly used. With these doses,
activity appeared no better than expected, which prompted early
closure of the study.
The excessive toxicity suggests an interaction between
gefitinib and the chemotherapy. An interaction between gefitinib
and 5-FU seems unlikely. Full doses of 5-FU/LV with gefitinib
were tolerated on various schedules, without apparent pharma-
cokinetic interactions (Hammond et al, 2001). Gefitinib 250mg
can be administered with full doses of oxaliplatin/5-FU
with tolerable toxicity, although a higher incidence of diarrhoea
may suggest a possible pharmacodynamic interaction (Fisher
et al, 2004).
The profile of side effects in our study suggests an interaction
with irinotecan rather than with 5-FU. Irinotecan is metabolised
in the liver by several enzyme systems (Kawato et al, 1991; Rivory
and Robert, 1995; Haaz et al, 1997; Xie et al, 2002). Cleavage by
carboxylesterase yields the active metabolite SN-38, which is
inactivated by glucuronide conjugation by uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) (Haaz et al, 1997), variable
Table 1 Patient characteristics
No. of patients
Entered 13
Assessable 12
Sex
Male 6
Female 7
Age (years)
Range 49–72
Median 58
ECOG performance status
10
12
21
Site of tumour
Colon 12
Rectum 1
Liver involvement 10
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sactivity of which is a determinant of toxicity (Innocenti et al,
2004). Another pathway involves oxidation of the terminal
piperidine ring by the P450 enzyme, CYP3A4 (Rivory et al, 1996;
Dodds et al, 1998), of which gefitinib is a weak inhibitor.
Additionally, mild elevations of bilirubin have been shown to
predict neutropenia with weekly irinotecan, implicating hepatic
excretion (Meyerhardt et al, 2004).
Iacono et al reported a study of gefitinib and irinotecan in
children. Concomitant administration of gefitinib reduced irino-
tecan clearance and increased the AUC of SN-38 (Iacono et al,
2004). In another phase I clinical trial (Chau et al, 2004) of
gefitinib with irinotecan, dose reduction was required. We propose
that the interaction of irinotecan and gefitinib in our trial is likely
to have been pharmacokinetic, resulting in greater than anticipated
exposure to irinotecan and its active metabolite. Interestingly,
Messersmith et al (2004) have recently reported excessive toxicity
requiring early closure of the study in a phase I trial of a
combination of erlotinib with reduced doses of irinotecan and
infusional 5-FU. A pharmacokinetic interaction between irino-
tecan, 5-FU, and erlotinib could not explain the toxicity.
Additionally, blockage of the EGFR may not account for this level
of toxicity since combination of Erbitux with irinotecan has not
resulted in such severe toxicity (Cunningham et al, 2004). An
interaction between gefitinib and the multidrug resistance ABC
Table 3 Toxicity related to the combination of irinotecan/FU/LV/gefitinib by cycle
Toxicity Cycle 1 (N¼13) Cycle 2 (N¼10) Cycle 3 (N¼7) Cycle 4 (N¼7) Cycle 5 (N¼6) Cycle 6 (N¼4)
Diarrhoea
Grade 1 or 2 5 3 2 2 3 2
Grade 3 or 4 2 2 0 2 0 1
Nausea/vomiting
Grade 1 or 2 7 5 4 2 2 3
Grade 3 or 4 0 0 0 0 0 0
Dehydration
Grade 1 or 2 1 0 0 0 0 0
Grade 3 or 4 3 3 0 1 0 0
Mucositis
Grade 1 or 2 2 0 0 0 0 0
Grade 3 or 4 0 0 0 0 0 0
Fatigue
Grade 1 or 2 6 5 1 1 2 2
Grade 3 or 4 0 0 0 0 0 0
Skin rash
Grade 1 or 2 6 3 3 1 1 1
Grade 3 or 4 0 0 0 0 0 0
Neutropenia
Grade 1 or 2 2 1 1 1 1 0
Grade 3 or 4 5 1 0 0 2 0
Neutropenic fever 2 1 0 0 0 0
Anaemia
Grade 1 or 2 5 0 1 0 0
Grade 3 or 4 1 0 0 0 0
5-FU¼5-fluorouracil; LV¼leucovorin.
Table 2 Toxicity related to the combination of irinotecan/5-FU/gefitinib by dose
N Maximum toxicity/grade
New
a Total
b Nonhaematologic Haematologic
D o s e G1 G2 G3 G4 G1 G2 G3 G4
I180/5-FU400–600 7 7 7 7 4 1 2 4 3 2
I150/5-FU320–500 4 7 4 4 3 0 0 1 1 2
I120/5-FU200–500 2 8 1 2 0 0 0 0 0 0
Gefitinib dose was 250mg daily and it was not reduced. 5-FU¼5-fluorouracil.
aNumber of patients who received the given irinotecan and 5-FU doses on cycle 1.
bNumber of
patients who received the given irinotecan and 5-FU doses on cycle 1 plus as reductions in subsequent cycles.
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stransporter could have contributed to toxicity. Gefitinib inhibits
ABCG2-dependent active drug extrusion, which mediates irinote-
can efflux and protects cells from irinotecan toxicity (Wierdl et al,
2003; Ozvegy-Laczka et al, 2004).
While both of these possibilities need consideration in using
these drugs in combination, the implied increase in sources of
intrapatient variability was perceived as a safety hazard for further
development on a solely empirical basis.
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